Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: An EORTC-STBSG study

Background: Pazopanib has activity in relapsed non-adipocytic soft-tissue sarcomas (STS). A series of serum cytokines and angiogenic factors (CAFs) at baseline and changes in soluble vascular endothelial growth factor receptor-2 (sVEGFR2) or placental-derived growth factor (PlGF) levels during treatment were explored for their association with outcome.Methods:Twenty-three baseline CAFs, and sVEGFR2 and PlGF changes were measured in 85 and 32 patients, respectively. Associations between baseline CAF levels and efficacy parameters, plus between-week 12 sVEGFR2 and PlGF levels and pazopanib-specific toxicities were investigated.Results:At baseline, low interleukin (IL)-12 p40 subunit and MPC3 levels were associated with better progression-free survival (PFS) at 12 weeks (PFS 12wks), low basic nerve growth factor and hepatocyte growth factor with a better PFS, and low inter-cellular adhesion molecule-1 and IL-2 receptor alpha with prolonged overall survival (OS; all P=0.05). Pazopanib decreased sVEGFR2 and increased PlGF levels. Low sVEGFR2 and high PlGF levels at week 12 were associated with higher-grade hypertension, with TSH elevations and with poorer PFS 12wks, and OS (both P=0.05).Conclusion:Several baseline CAFs were related to outcome parameters. Low sVEGFR2 and high PlGF at week 12 associate with several pazopanib-specific toxicities and poorer efficacy. If confirmed, these factors may be used as early markers for response to and toxicity from pazopanib, enabling further individualisation of STS treatment

Nanostructuration of soft hydrogels: synthesis and characterization of saccharidic methacrylate gels

International audienceWith the tremendous development of biosensors, there is a strong need in new biocompatible materials avoiding possible denaturing of biological species, which can be easily processed with already existing technologies. The scope of this study was to develop new hydrogels which could be nanostructured by common lithographic methods. Therefore, new methacrylate hydrogels are described, which include functionalized monomers bearing either neutral groups, such as saccharidic moieties, anionic, or cationic groups. The gels have been synthesized by redox or photochemical-initiated radical polymerization. Their porosity has been characterized by thermoporometry, AFM, and electronic microscopy. The kinetics of the photocross-linking has been analyzed by piezorheometry on some of the materials and has been shown to be compatible with technological process time range. Although the obtained hydrogels are soft, their nanostructuration into 500-nm patterns could be performed by nanoimprint photolithography process, and these patterns were observed to be stable for several months

Impact of Pathological Characteristics on Local Relapse After Breast-Conserving Therapy: A Subgroup Analysis of the EORTC Boost Versus No Boost Trial

Item does not contain fulltextPURPOSE: To investigate the long-term impact of pathologic characteristics and an extra boost dose of 16 Gy on local relapse, for stage I and II invasive breast cancer patients treated with breast conserving therapy (BCT). PATIENTS AND METHODS: In the European Organisation for Research and Treatment of Cancer boost versus no boost trial, after whole breast irradiation, patients with microscopically complete excision of invasive tumor, were randomly assigned to receive or not an extra boost dose of 16 Gy. For a subset of 1,616 patients central pathology review was performed. RESULTS: The 10-year cumulative risk of local breast cancer relapse as a first event was not significantly influenced if the margin was scored negative, close or positive for invasive tumor or ductal carcinoma in situ according to central pathology review (log-rank P = .45 and P = .57, respectively). In multivariate analysis, high-grade invasive ductal carcinoma was associated with an increased risk of local relapse (P = .026; hazard ratio [HR], 1.67), as was age younger than 50 years (P < .0001; HR, 2.38). The boost dose of 16 Gy significantly reduced the local relapse rate (P = .0006; HR, 0.47). For patients younger than 50 years old and in patients with high grade invasive ductal carcinoma, the boost dose reduced the local relapse from 19.4% to 11.4% (P = .0046; HR, 0.51) and from 18.9% to 8.6% (P = .01; HR, 0.42), respectively. CONCLUSION: Young age and high-grade invasive ductal cancer were the most important risk factors for local relapse, while margin status had no significant influence. A boost dose of 16 Gy significantly reduced the negative effects of both young age and high-grade invasive cancer

Um filho quando eu quiser?: o caso da França contemporânea A child if I want when I want… Reviewing women's aspiration through IVF uses in a French Hospital

A livre escolha da maternidade e do momento de vivê-la foram reivindicações centrais e unânimes do movimento de mulheres nos anos 1970. Em uma primeira fase, esse embate foi amplamente acompanhado por profissionais da área médica, com a difusão de práticas medicalizadas de contracepção e de aborto. Em contrapartida, as tecnologias reprodutivas que permitem adiar a idade da maternidade foram acolhidas com controvérsias pelas feministas: será que essa medicalização da procriação contribuiria para libertar as mulheres dos limites cronológicos ou, pelo contrário, as confinaria a um destino maternal? É essa questão que esse artigo pretende esclarecer, a partir da experiência social da fecundação in vitro nas duas últimas décadas, sobretudo a realizada em um hospital francês.<br>Choosing freely motherhood and its calendar was a central and unanimous claim of the women's lib in the seventies. First, women and professionals belonging to the medical circle fought together to make contraception and abortion available. Nevertheless, feminists have been divided before reproductive technologies that could allow to delay pregnancies: would this medicalization of procreation contribute to emancipate women from time constraints or, on the contrary, contribute to lock them into a maternal destiny? This paper will try to shed light on this problem by discussing IVF social experience in France during the last two decades

Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity.

Sarcomas are heterogeneous and aggressive mesenchymal tumors. Histological grading has so far been the best predictor for metastasis-free survival, but it has several limitations, such as moderate reproducibility and poor prognostic value for some histological types. To improve patient grading, we performed genomic and expression profiling in a training set of 183 sarcomas and established a prognostic gene expression signature, complexity index in sarcomas (CINSARC), composed of 67 genes related to mitosis and chromosome management. In a multivariate analysis, CINSARC predicts metastasis outcome in the training set and in an independent 127 sarcomas validation set. It is superior to the Fédération Francaise des Centres de Lutte Contre le Cancer grading system in determining metastatic outcome for sarcoma patients. Furthermore, it also predicts outcome for gastrointestinal stromal tumors (GISTs), breast carcinomas and lymphomas. Application of the signature will permit more selective use of adjuvant therapies for people with sarcomas, leading to decreased iatrogenic morbidity and improved outcomes for such individuals